Ascletis

company

About

Ascletis is a specialty therapeutics company developing therapeutics for the treatment of cancer and infectious diseases.

  • 251 - 500

Details

Last Funding Type
Series B
Last Funding Money Raised
$100M
Industries
Health Care,Medical,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
251 - 500
Operating Status
Active

Ascletis is a joint venture between U.S. and Chinese entrepreneurs aimed at building a global specialty therapeutics business dedicated to discovering and developing important new treatments for cancer and infectious diseases. Ascletis leverages U.S./European innovation and pharmaceutical/biotech strategic experience and China's capital efficiency with a goal of establishing in the near term a sustainable business and accelerated revenues through the in-licensing, late-stage clinical development, and commercialization of new medicines for the growing Chinese pharmaceutical marketplace. At the same time, the company is building long-term value through the discovery, demonstration of clinical proof-of-concept, and global partnering of novel therapeutics for life-threatening diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$200M
Ascletis has raised a total of $200M in funding over 2 rounds. Their latest funding was raised on Jan 3, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 3, 2017 Series B $100M 2 Detail
Apr 6, 2011 Series A $100M 1 Hangzhou Binjiang Investment Holding Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Ascletis is funded by 3 investors. Hangzhou Binjiang Investment Holding and WTT Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Hangzhou Binjiang Investment Holding Yes Series A
WTT Investment Series B
QianHai Equity Investment Series B